TY  - JOUR
AU  - Kebir, Sied
AU  - Schaub, Christina
AU  - Junold, Nina
AU  - Hattingen, Elke
AU  - Schäfer, Niklas
AU  - Steinbach, Joachim P.
AU  - Weyerbrock, Astrid
AU  - Hau, Peter
AU  - Goldbrunner, Roland
AU  - Galldiks, Norbert
AU  - Weller, Johannes
AU  - Mack, Frederic
AU  - Tzaridis, Theophilos
AU  - Bähr, Oliver
AU  - Seidel, Clemens
AU  - Schlegel, Uwe
AU  - Schmidt-Graf, Friederike
AU  - Rohde, Veit
AU  - Borchers, Christian
AU  - Tabatabai, Ghazaleh
AU  - Hänel, Mathias
AU  - Sabel, Michael
AU  - Gerlach, Rüdiger
AU  - Krex, Dietmar
AU  - Belka, Claus
AU  - Vatter, Hartmut
AU  - Proescholdt, Martin
AU  - Glas, Martin
AU  - Herrlinger, Ulrich
TI  - Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial
JO  - Journal of neuro-oncology
VL  - 144
IS  - 3
SN  - 1573-7373
CY  - Dordrecht [u.a.]
PB  - Springer Science + Business Media B.V
M1  - FZJ-2019-03906
SP  - 501-509
PY  - 2019
AB  - PurposeThe phase II GLARIUS trial assigned patients with newly diagnosed, O-6-methylguanine-DNA methyltransferase promoter non-methylated glioblastoma to experimental bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ). To identify subpopulations with a particularly favorable course, we assessed the prognostic potential of magnetic resonance imaging (MRI) markers before treatment onset.MethodsMRIs at baseline (before treatment onset) were analyzed for T1-hyperintense and diffusion-restricted lesions; as well as the presence of both hyperintense and diffusion-restricted (double positive) lesions. The MRI findings were correlated with overall and progression-free survival.ResultsMRI scans were evaluable in 71% of the GLARIUS modified intention-to-treat population (n = 121 of 170; 88 patients in the BEV/IRI arm, and 33 patients in the TMZ control arm). Diffusion-restricted and T1 hyperintense lesions were present in 60% and 65% of patients in BEV/IRI arm, while 57% and 63% were found in the TMZ arm, respectively. Double positive lesions were found in 37% of BEV/IRI patients and in 39% of TMZ patients. Neither the presence of T1-hyperintense, diffusion-restricted lesions, nor double positive lesions were associated with improved survival.ConclusionsBaseline T1-hyperintense and diffusion-restricted lesions are not suitable to predict progression-free or overall survival of patients treated with bevacizumab/irinotecan or temozolomide.
LB  - PUB:(DE-HGF)16
C6  - pmid:31325144
UR  - <Go to ISI:>//WOS:000487899900008
DO  - DOI:10.1007/s11060-019-03246-4
UR  - https://juser.fz-juelich.de/record/863990
ER  -